Executive Function

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62

Presence of MSIMI at baseline was associated with 33% greater increase in Trail-B score over 2 years of follow-up, indicating faster executive function decline, and this association was partly mediate

Effect: decline; B 0.33; CI: 95% CI 0.04, 0.62